Ritanserin

Ritanserin is a serotonin antagonist that was discovered and developed by Janssen Pharmaceutica in the 1980s. It is classified as a second-generation antipsychotic (SGA) and has been used in the treatment of various psychiatric disorders.

History

Ritanserin was first synthesized by Janssen Pharmaceutica in the 1980s. The drug was developed as part of a new class of antipsychotics known as second-generation antipsychotics, which were designed to be more effective and have fewer side effects than first-generation antipsychotics.

Pharmacology

Ritanserin acts as an antagonist at the 5-HT2A receptor and 5-HT2C receptor, which are both subtypes of the serotonin receptor. By blocking these receptors, ritanserin can reduce the effects of serotonin, a neurotransmitter that is thought to play a role in mood and anxiety disorders.

Clinical uses

Ritanserin has been used in the treatment of a variety of psychiatric disorders, including schizophrenia, anxiety disorders, and depression. It has also been investigated for its potential use in the treatment of insomnia, due to its ability to block the effects of serotonin, which can promote wakefulness.

Side effects

Like all medications, ritanserin can cause side effects. The most common side effects of ritanserin include drowsiness, dry mouth, and constipation. In rare cases, ritanserin can cause serious side effects, such as abnormal heart rhythms or severe allergic reactions.

See also

• Serotonin antagonist
• Second-generation antipsychotic
• 5-HT2A receptor
• 5-HT2C receptor